Abbott Laboratories (NYSE:ABT) Announces Quarterly Dividend of $0.63

Abbott Laboratories (NYSE:ABT) declared a quarterly dividend on Friday, June 12th. Investors of record on Wednesday, July 15th will be given a dividend of 0.63 per share by the healthcare product maker on Monday, August 17th. This represents a c) dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Wednesday, July 15th.

Abbott Laboratories has increased its dividend by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 54 consecutive years. Abbott Laboratories has a dividend payout ratio of 44.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Abbott Laboratories to earn $6.05 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.7%.

Abbott Laboratories Price Performance

Shares of ABT opened at $93.97 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a market cap of $163.69 billion, a PE ratio of 26.32, a PEG ratio of 1.62 and a beta of 0.61. The firm’s 50 day moving average price is $89.21 and its 200 day moving average price is $103.09. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company’s stock.

Institutional Trading of Abbott Laboratories

Hedge funds have recently modified their holdings of the company. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories during the 4th quarter worth $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories in the fourth quarter worth $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $26,000. Finally, Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.